The efficiency and value of the nation’s Prescription Drug Monitoring Programs (PDMPS) have been questioned from time to time by various groups.
A commonly held axiom in specialty pharmacy is that the patient is at the center of every action.
The trial of Michael Jackson's doctor will highlight the problem of prescription drug abuse, and expose systematic failures of the US health care system.
Pharmacists can make clinical recommendations tailored to patients’ individual needs.
We describe enrollment in a voluntary VBID initiative. Uptake was suboptimal, suggesting that barriers to enrollment may have significant implications for the overall effectiveness of VBID.
Atrial fibrillation, the most common cardiac arrhythmia, is strongly associated with increased morbidity and mortality and has become a major global public health challenge.
Specialty pharmacies must plan carefully to ensure compliance with new supply chain rules.
When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.
An extremely virulent (hypermucoviscous) strain of Klebsiella pneumoniae (K pneumoniae) that is resistant to carbapenem and colistin has been isolated for the first time from a patient in the United States.
Prior to the president's final State of the Union address, Democrats announced new plans to investigate drug prices in 2016.
The findings of the retrospective cohort study were presented in a poster at IDWeek 2019.
Helpful advice for your patients on treating bacterial skin infections.
Postoperative pain management presents a major challenge to patients and health care providers.
An Effective Treatment Plan Is Crucial for Patients with Crohn's Disease and Ulcerative Colitis.
Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.
Here is an overview of the key Issues for hospital pharmacists.
A proposal to reduce Medicare Part B payment rates for hospitals participating in the 340B Drug Pricing Program has been approved 14-3 by the Medicare Payment Advisory Commission.